NPS Direct – June 2013
Published in NPS Direct
Date published: About this date
When to perform prostate cancer tests
Deciding whether to test for prostate cancer is a complex issue with multiple contributing factors. It can be difficult to explain all of the issues to a man who has asked about testing. Having an understanding of the latest evidence will help. Read more
Statins and kidney injury
A recent study suggested that the risk of acute kidney injury is higher in patients taking high potency statins compared with those taking low potency statins. Find out which drugs are involved and what this means for your patients. Read more
Duration of antibiotic therapy and resistance
Continued overuse and misuse of antibiotics means we risk losing the impact of these vital medicines. Outlining the duration of antibiotic therapy for your patients can help ensure antibiotics are taken as intended.
Five messages from NPS MedicineWise about:
Preventive health — which tests make a difference?
1. Launching a new education program
The new program focuses on preventive activities in general practice and highlights the opportunity to modify the growing burden of chronic disease in Australia. Do you want to get involved and request an educational visit?
2. The growing burden of chronic disease
Over 7 million Australians have a chronic condition and many more are at risk of developing one in the future. By modifying your patients' lifestyle risk factors you could prevent the growing burden.
3. Targeting people in their 40s
4. Which tests make a difference?
Consider the evidence base for medical tests and only request tests during preventive activities that are recommended in the RACGP red book. These tests can identify risk in apparently healthy people.
5. Three tests with no proven benefit
Not all tests are appropriate for routine testing in healthy, low risk patients and are not recommended during preventive activities.
- prostate-specific antigen test for prostate cancer
- vitamin D tests
- thyroid function tests.
Rivaroxaban PBS listed for deep vein thrombosis
Rivaroxaban is now PBS listed for the treatment of DVT and prevention of venous thromoboembolism recurrence. How does rivaroxaban compare with standard treatment of DVT? Which patients are suitable and eligible for treatment?
A recent report showed that some communities have low vaccination rates, increasing risk of disease outbreaks. Good communication ensures maximum immunisation uptake and GPs are vitally important to this process.
New reports assist QUM in residential aged-care facilities
NPS MedicineWise and Webstercare have designed a new reporting function within Webstercare Medication Management Software. Pharmacists can create in depth reports for each facility they supply to help them understand and analyse their antipsychotic medicine usage.
For pharmacists — promoting safe use of oral anticoagulants
Want to know more about the safe use of the new oral anticoagulants how they compare to warfarin? Register free for our latest Pharmacy Practice Review. Earn 8 hours of Group 2 CPD points (16 credits).
Please take a couple of minutes to answer a few questions and let us know what you think about NPS Direct. We also welcome suggestions for what you would like to receive in future issues. Talk to us about NPS Direct.